Hansoh Pharmaceutical (03692) Regains Global Rights to Aumolertinib for Development, Manufacturing, and Commercialization Outside China

Hansoh Pharma (03692) announced that the group has received a written notice from EQRx, Inc. (EQRx) regarding the termination of the strategic cooperation and license agreement (the "License Agreement") entered into on July 23, 2023, between EQRx and the group's subsidiaries, Hansoh (Shanghai) Health Technology Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. The License Agreement will terminate upon the expiration of the term specified in the agreement. Upon termination of the License Agreement, the group will regain the rights to research, develop, manufacture, and commercialize Aumolertinib outside of China. The termination of the License Agreement will not affect the upfront payment and milestone payments previously received by the group from EQRx. Both parties will subsequently discuss and determine the corresponding transition arrangements.

The marketing authorization application (MAA) for Aumolertinib for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations, and for the treatment of adult patients with locally advanced or metastatic NSCLC positive for the EGFR T790M mutation, is currently under review by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). After the transition is completed, the group will be responsible for advancing the regulatory process for the MHRA and EMA’s review of Aumolertinib’s MAA.